Cogent Biosciences, Inc.
Pharmaceutical Preparations
Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
What Cogent Biosciences, Inc. reports
Revenue and net income below are for fiscal period FY2020, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.
Where the employee count comes from
Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.
Insiders at Cogent Biosciences, Inc.
Shares is what each person last reported holding here.
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
Rows are grouped by the role each person reports.
The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.
| Insider | Reported role | Shares | Value | Last action |
|---|---|---|---|---|
| Officers 5 | ||||
Cole Pinnow
|
Other Executive | 216,650 | $7.53M | A Grant or award Dec 17, 2025 position reported |
| John Edward Robinson | Other Executive | 140,002 | $4.87M | S Open-market sale Dec 26, 2025 position reported |
| Jessica Sachs | Other Executive | 133,938 | $4.66M | S Open-market sale Dec 26, 2025 position reported |
John L Green
|
CFO | 131,834 | $4.58M | S Open-market sale Dec 26, 2025 position reported |
| Evan Kearns | General Counsel | 109,398 | $3.80M | S Open-market sale Dec 26, 2025 position reported |
| Officers who also sit on the board 1 | ||||
Andrew R Robbins
|
CEO | 657,503 | $22.85M | G Bona fide gift May 19, 2026 position reported |
Recent insider transactions
Of the 25 rows we hold, 1 are open-market purchases (P) and 4 open-market sales (S) — the only codes we count as buying or selling.
The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.
A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 19, 2026 | Andrew R Robbins | G Bona fide gift | 160,000 | $0.00 | $0 | SEC filing ↗ |
| May 19, 2026 | Andrew R Robbins | G Bona fide gift | 160,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 26, 2025 | John Edward Robinson | S Open-market sale | 90,000 | $38.74 | $3.49M | SEC filing ↗ |
| Dec 26, 2025 | Jessica Sachs | S Open-market sale | 82,642 | $38.70 | $3.20M | SEC filing ↗ |
| Dec 26, 2025 | Evan Kearns | S Open-market sale | 65,000 | $38.70 | $2.52M | SEC filing ↗ |
| Dec 26, 2025 | John L Green | S Open-market sale | 77,000 | $38.68 | $2.98M | SEC filing ↗ |
| Dec 17, 2025 | Cole Pinnow | A Grant or award | 50,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 17, 2025 | Cole Pinnow | F Shares withheld for taxes | 94,800 | $39.45 | $3.74M | SEC filing ↗ |
| Dec 17, 2025 | Cole Pinnow | A Grant or award | 214,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 17, 2025 | John Edward Robinson | A Grant or award | 320,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 17, 2025 | John Edward Robinson | F Shares withheld for taxes | 139,998 | $39.45 | $5.52M | SEC filing ↗ |
| Dec 17, 2025 | John Edward Robinson | A Grant or award | 50,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 17, 2025 | Jessica Sachs | A Grant or award | 50,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 17, 2025 | Jessica Sachs | A Grant or award | 320,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 17, 2025 | Jessica Sachs | F Shares withheld for taxes | 154,716 | $39.45 | $6.10M | SEC filing ↗ |
| Dec 17, 2025 | Evan Kearns | F Shares withheld for taxes | 125,602 | $39.45 | $4.95M | SEC filing ↗ |
| Dec 17, 2025 | Evan Kearns | A Grant or award | 260,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 17, 2025 | Evan Kearns | A Grant or award | 40,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 17, 2025 | John L Green | A Grant or award | 300,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 17, 2025 | John L Green | A Grant or award | 50,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 17, 2025 | John L Green | F Shares withheld for taxes | 145,007 | $39.45 | $5.72M | SEC filing ↗ |
| Dec 17, 2025 | Andrew R Robbins | A Grant or award | 840,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 17, 2025 | Andrew R Robbins | A Grant or award | 185,000 | $0.00 | $0 | SEC filing ↗ |
| Dec 17, 2025 | Andrew R Robbins | F Shares withheld for taxes | 367,497 | $39.45 | $14.50M | SEC filing ↗ |
| Jan 14, 2025 | Cole Pinnow | P Open-market purchase | 43,750 | $7.60 | $332.5K | SEC filing ↗ |
From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.
What a Form 4 is
The report an officer, director or large shareholder must file after trading their own company’s stock.
Corporate ownership links — 1 filer holds a position
Who owns Cogent Biosciences, Inc.
Each row is one filer naming this company.
Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.
Filers holding a position in Cogent Biosciences, Inc.
| Owner | Reported role | Shares | Filed |
|---|---|---|---|
| Fairmount Funds Management LLC | Director,TenPercentOwner | 5,503,418 |
See the full ownership map — every entity that files as an owner of a US public company.
Subsidiaries — 2 legal entities
Subsidiaries of Cogent Biosciences, Inc.
2 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.
This is not the full list. SEC rules only require a company to name its significant subsidiaries.
What that leaves out
Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.
| Subsidiary | Organised in |
|---|---|
| Kiq Bio LLC | Delaware |
| Mono Inc. | Massachusetts |
What counts as a subsidiary
A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.
Think a number here is wrong? Open the linked filing and compare — how to report it.
Sources and technical notes
Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.
Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from
Cogent Biosciences, Inc.’s own filings and multiplied by our closing price.
Full method.
What that share count means
the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.
We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Cogent Biosciences, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.